NO20052921L - Fenylsubstituerte piperidinforbindelser for anvendelse som PPAR aktivatorer - Google Patents

Fenylsubstituerte piperidinforbindelser for anvendelse som PPAR aktivatorer

Info

Publication number
NO20052921L
NO20052921L NO20052921A NO20052921A NO20052921L NO 20052921 L NO20052921 L NO 20052921L NO 20052921 A NO20052921 A NO 20052921A NO 20052921 A NO20052921 A NO 20052921A NO 20052921 L NO20052921 L NO 20052921L
Authority
NO
Norway
Prior art keywords
levels
phenyl
cholesterol
piperidine compounds
substituted piperidine
Prior art date
Application number
NO20052921A
Other languages
English (en)
Other versions
NO20052921D0 (no
Inventor
Scott William Bagley
Cheryl Myers Hayward
Robert Wayne Dugger
Zhengyu Liu
Thomas Andrew Brandt
William Andrew Hada
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20052921D0 publication Critical patent/NO20052921D0/no
Publication of NO20052921L publication Critical patent/NO20052921L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Det beskrives PPARoc aktivatorer, farmasøytiske preparater inneholdende slike forbindelser samt anvendelsen av disse for å forhøye visse plasmalipidnivåer inkludert høydensitets lipoprotein kolesterolnivåer og å redusere visse andre plasmalipidnivåer som LDL-kolesterol- og triglyseridnivåer. I henhold til dette angår oppfinnelsen behandling av sykdommer som eksaserberer ved lave nivåer av HDL, kolesterol og/eller høye nivåer av LDL-kolesterol og triglyserider, for eksempel aterosklerose og kardiovaskulære sykdommer i pattedyr og særlig mennesker.
NO20052921A 2002-11-26 2005-06-15 Fenylsubstituerte piperidinforbindelser for anvendelse som PPAR aktivatorer NO20052921L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42950602P 2002-11-26 2002-11-26
PCT/IB2003/005235 WO2004048334A1 (en) 2002-11-26 2003-11-14 Phenyl substituted piperidine compounds for use as ppar activators

Publications (2)

Publication Number Publication Date
NO20052921D0 NO20052921D0 (no) 2005-06-15
NO20052921L true NO20052921L (no) 2005-08-18

Family

ID=32393563

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052921A NO20052921L (no) 2002-11-26 2005-06-15 Fenylsubstituerte piperidinforbindelser for anvendelse som PPAR aktivatorer

Country Status (33)

Country Link
US (2) US7199243B2 (no)
EP (1) EP1567493B1 (no)
JP (1) JP4029091B2 (no)
KR (2) KR100760055B1 (no)
CN (1) CN100439337C (no)
AR (1) AR042131A1 (no)
AT (1) ATE425966T1 (no)
AU (1) AU2003276596B8 (no)
BR (1) BR0316521A (no)
CA (1) CA2507465C (no)
CO (1) CO5570701A2 (no)
DE (1) DE60326752D1 (no)
DK (1) DK1567493T3 (no)
EA (1) EA008928B1 (no)
ES (1) ES2321509T3 (no)
GT (1) GT200300258A (no)
HR (1) HRP20050437A2 (no)
IS (1) IS7816A (no)
MA (1) MA27532A1 (no)
MX (1) MXPA05005583A (no)
NL (1) NL1024881C2 (no)
NO (1) NO20052921L (no)
NZ (1) NZ539546A (no)
PE (1) PE20040699A1 (no)
PL (1) PL378268A1 (no)
PT (1) PT1567493E (no)
SI (1) SI1567493T1 (no)
TN (1) TNSN05146A1 (no)
TW (1) TW200424172A (no)
UA (1) UA83202C2 (no)
UY (1) UY28097A1 (no)
WO (1) WO2004048334A1 (no)
ZA (1) ZA200503104B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05005583A (es) * 2002-11-26 2005-07-27 Pfizer Prod Inc Activadores de ppar.
BRPI0511613A (pt) * 2004-05-25 2008-01-02 Pfizer Prod Inc uso de agonista de ppar
CA2567398A1 (en) * 2004-05-25 2005-12-08 Pfizer Products Inc. New use
CN101014595A (zh) 2004-08-11 2007-08-08 杏林制药株式会社 新型环状氨基苯甲酸衍生物
DE602005016009D1 (de) * 2004-11-23 2009-09-24 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure-derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
US20090036489A1 (en) * 2005-03-22 2009-02-05 Masahiro Nomura Novel Cyclic Aminophenylalkanoic Acid Derivative
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
WO2007023882A1 (ja) * 2005-08-26 2007-03-01 Shionogi & Co., Ltd. Ｐｐａｒアゴニスト活性を有する誘導体
US9173875B2 (en) * 2006-04-11 2015-11-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Treatment for nicotine-induced lung disease using peroxisome proliferator-activated receptor gamma agonists
WO2008065626A2 (en) * 2006-12-01 2008-06-05 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperidine derivativesas orexin receptor inhibitors
WO2009011872A1 (en) * 2007-07-17 2009-01-22 Merck & Co., Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
SG187396A1 (en) 2007-07-19 2013-02-28 Lundbeck & Co As H 5-membered heterocyclic amides and related compounds
TW201006816A (en) 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
FR2935511B1 (fr) 2008-08-28 2010-12-10 Oberthur Technologies Procede d'echange de donnees entre deux entites electroniques
FR2935510B1 (fr) 2008-08-28 2010-12-10 Oberthur Technologies Procede d'echange de donnees entre deux entites electroniques
UA107938C2 (en) 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
WO2011037793A1 (en) * 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Substituted aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
TWI513695B (zh) * 2009-10-27 2015-12-21 Merck Sharp & Dohme （１，１，１，３，３，３－六氟－２－羥基丙－２－基）苯基衍生物
EP2363825B1 (fr) 2010-03-04 2016-04-27 Inside Secure Procédé pour conduire une transaction au moyen d'un dispositif NFC
WO2012120414A2 (en) 2011-03-04 2012-09-13 Pfizer Inc. Edn3-like peptides and uses thereof
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
RU2615769C2 (ru) * 2015-07-29 2017-04-11 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования "Уфимский Государственный Университет Экономики И Сервиса" Средство для ингибирования фермента альфа-амилазы
US20220411372A1 (en) * 2019-09-20 2022-12-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small-molecule inhibitors for the b-catenin/b-cell lymphoma 9 protein-protein interaction
CN116162056A (zh) * 2021-11-24 2023-05-26 上海医药工业研究院 β-catenin/BCL9蛋白-蛋白相互作用的小分子抑制剂及其应用
WO2024022521A1 (zh) * 2022-07-28 2024-02-01 南通环聚泰生物科技有限公司 靶向BCL9/β-连环蛋白互相作用的小分子化合物
WO2024145931A1 (zh) * 2023-01-06 2024-07-11 上海医药工业研究院有限公司 β-catenin/BCL9蛋白蛋白相互作用的小分子抑制剂及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2025518A1 (no) * 1969-06-05 1970-12-10
US4476311A (en) * 1980-03-12 1984-10-09 The Purdue Frederick Company Analgesic 4-carboxy-pyrrolidin-2-one compound
EP0077607A1 (en) * 1981-09-17 1983-04-27 Beecham Group Plc N-substituted 3-aryl piperidines and derivatives thereof
EP0115607A1 (de) * 1983-01-04 1984-08-15 MERCK PATENT GmbH Tetrahydrocarbazolderivate
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
US5274143A (en) * 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
AU2869092A (en) 1991-10-11 1993-05-03 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
WO1993012086A1 (fr) * 1991-12-11 1993-06-24 Ss Pharmaceutical Co., Ltd. Derive d'arylamide
JPH05255089A (ja) * 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
JP3233991B2 (ja) * 1992-06-26 2001-12-04 株式会社ソフィア 遊技機
ES2156120T3 (es) * 1992-12-08 2001-06-16 Ss Pharmaceutical Co Derivados arilamidicos.
WO1996002250A1 (en) 1994-07-20 1996-02-01 Acea Pharmaceuticals Inc. Haloperidol analogs and the use thereof
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
DE19614204A1 (de) * 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JPH09312086A (ja) * 1996-05-22 1997-12-02 Matsushita Electric Ind Co Ltd 光ディスク再生システム、光ディスク再生方法および光ディスク
AU4050797A (en) 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
IT1286497B1 (it) * 1996-11-20 1998-07-15 Italfarmaco Sud Spa Difosfine di tipo misto eteroariliche-ariliche come leganti chirali, relativi complessi con metalli di transizione e impiego di detti
SK9212000A3 (en) * 1997-12-19 2001-02-12 Merck & Co Inc Arylthiazolidinedione derivatives, pharmaceutical compositions comprising the same and use thereof
DE69919436T2 (de) * 1998-04-16 2005-09-15 Pfizer Products Inc., Groton N-Acyl und N-Aroyl Aralkylamide
US6376494B1 (en) * 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
HN1999000149A (es) 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
GB9822473D0 (en) 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
US6303637B1 (en) * 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
CA2324330A1 (en) * 1999-11-08 2001-05-08 Ssp Co., Ltd. 4-hydroxy-4-phenylpiperidine derivatives and pharmaceuticals containing the same
US20020045613A1 (en) 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
AU2000258650A1 (en) 2000-05-11 2001-11-20 Eli Lilly And Co 2-piperidone compounds for the treatment of cancer
MXPA02011400A (es) 2000-05-22 2003-05-23 Aventis Pharm Prod Inc Derivados de arimetilamina para uso como inhibidores de triptasa.
AU2001211337A1 (en) 2000-10-06 2002-04-15 Smithkline Beecham Plc Process for the preparation of aryl-piperidine carbinols and intermediates thereof
AU2001294240A1 (en) 2000-10-12 2002-04-22 Ssp Co., Ltd. 2,2-diphenylbutanamide derivatives and medicines containing the same
JP2002173426A (ja) 2000-12-05 2002-06-21 Ss Pharmaceut Co Ltd 血糖低下剤
WO2002064139A1 (en) * 2001-02-15 2002-08-22 Neurosearch A/S Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity
CA2438551A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
MXPA05005583A (es) * 2002-11-26 2005-07-27 Pfizer Prod Inc Activadores de ppar.

Also Published As

Publication number Publication date
NO20052921D0 (no) 2005-06-15
CO5570701A2 (es) 2005-10-31
BR0316521A (pt) 2005-10-04
KR100875318B1 (ko) 2008-12-22
CA2507465A1 (en) 2004-06-10
US20070191429A1 (en) 2007-08-16
ES2321509T3 (es) 2009-06-08
CA2507465C (en) 2009-04-28
AR042131A1 (es) 2005-06-08
AU2003276596B8 (en) 2009-03-05
TW200424172A (en) 2004-11-16
KR100760055B1 (ko) 2007-09-18
NL1024881C2 (nl) 2009-09-16
MA27532A1 (fr) 2005-09-01
EA200500629A1 (ru) 2005-12-29
DE60326752D1 (de) 2009-04-30
EP1567493B1 (en) 2009-03-18
DK1567493T3 (da) 2009-06-08
HRP20050437A2 (en) 2005-10-31
NZ539546A (en) 2007-11-30
PE20040699A1 (es) 2004-10-23
JP4029091B2 (ja) 2008-01-09
US7199243B2 (en) 2007-04-03
NL1024881A1 (nl) 2004-05-27
KR20050086794A (ko) 2005-08-30
GT200300258A (es) 2004-11-30
UY28097A1 (es) 2004-06-30
PL378268A1 (pl) 2006-03-20
PT1567493E (pt) 2009-04-09
ZA200503104B (en) 2006-12-27
WO2004048334A1 (en) 2004-06-10
EA008928B1 (ru) 2007-08-31
SI1567493T1 (sl) 2009-06-30
KR20070063051A (ko) 2007-06-18
CN1717389A (zh) 2006-01-04
JP2006509001A (ja) 2006-03-16
AU2003276596B2 (en) 2009-02-12
IS7816A (is) 2005-04-20
UA83202C2 (ru) 2008-06-25
HK1083502A1 (zh) 2006-07-07
MXPA05005583A (es) 2005-07-27
ATE425966T1 (de) 2009-04-15
EP1567493A1 (en) 2005-08-31
TNSN05146A1 (fr) 2007-05-14
CN100439337C (zh) 2008-12-03
US20040157885A1 (en) 2004-08-12
AU2003276596A1 (en) 2004-06-18

Similar Documents

Publication Publication Date Title
NO20052921L (no) Fenylsubstituerte piperidinforbindelser for anvendelse som PPAR aktivatorer
NO20073025L (no) Dibenzylaminforbindelser og derivater
WO2006045010A3 (en) Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
TW200508222A (en) Quinoline and quinoxaline compounds
MY130670A (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
MY121838A (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
BR0207285A (pt) Agonistas de ppar
NO20071510L (no) 4-Amino-substituerte-2-substituerte-1,2,3,4-tetrahydrokinolinforbindelser
NO20083642L (no) Dibenzylaminderivater som CETP-inhibitorer
NO20070511L (no) Substituerte heteroaryl- og fenylsulfamoylforbindelser
MY121405A (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
NO20075731L (no) Inhibitorer av mikrosomalt triglyceridtransferprotein og APO-B-sekresjon
NO20064615L (no) Substituerte heteroaryl- og fenylsulfamoylforbindelser
TW200612977A (en) Apolipoprotein A1 mimetics and uses thereof
MXPA05012570A (es) Derivados de tetrahidroisoquinolina como activadores de ppar-a.
NO20083641L (no) Dibenzylaminforbindelser, samt derivater derav
IL160533A0 (en) Methods of screening molecules that are used to prevent cardiovascular diseases
TW200616964A (en) Quinoline compounds
BRPI0607839A2 (pt) compostos 1,1,1-triflúor-3-[(benzil)-(pirimidin-2-il)-amino]-propan- 2-ol substituìdos
WO2008070496A3 (en) N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
NO20070140L (no) Mediatorer av revers kolesteroltransport for behandling av hyperkolesterolemi
DOP2002000327A (es) Agonistas de ppar
UY27168A1 (es) Agonistas de ppar
DOP2003000762A (es) Activadores de ppar
DOP2002000331A (es) Compuesto de ppar

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application